TMCnet News
Alzheon to Present at Upcoming Investor ConferencesAlzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders, today announced that the company will present at these upcoming investor conferences:
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer's clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer's disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been tested in clinical trials involving over 2,000 Alzheimer's patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160921005279/en/ |